Abstract
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not known. Here we establish by genetic, biochemical and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910. Thus targeting energy metabolism is a new, promising approach for antibacterial drug discovery. © 2007 Nature Publishing Group.
Original language | English |
---|---|
Pages (from-to) | 323-324 |
Journal | Nature Chemical Biology |
Volume | 3 |
DOIs | |
Publication status | Published - 2007 |